Apixaban: First global approval

Drugs

Volumn 71, Issue 15, 2011, Pages 2079-2089

  Watson, Julia ^a   Whiteside, Glen ^a   Perry, Caroline ^b  

^a R and D Insight   (New Zealand)

^b ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Acute coronary syndromes; Apixaban, general; Atrial fibrillation; Deep vein thrombosis, prevention; Low molecular weight heparins, therapeutic use; Pulmonary embolism, prevention; Stroke, prevention; Venous thromboembolism, prevention; Venous thromboembolism, treatment; Warfarin, therapeutic use

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; BMS 562247 01; ENOXAPARIN; FONDAPARINUX; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; PLACEBO; TINZAPARIN; UNCLASSIFIED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FOOD; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HIP ARTHROPLASTY; HUMAN; KIDNEY FAILURE; KNEE ARTHROPLASTY; LIVER TOXICITY; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; PYRAZOLES; PYRIDONES; STROKE; VENOUS THROMBOEMBOLISM;

EID: 80053997769     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11596820-000000000-00000     Document Type: Article

References (44)

1. Bristol-Myers Squibb. ECS 2011 Highlights: Investor Meeting, 28 August 2011 World Wide Web [online]. 31 Aug 2011. Available from URL: http://www.bms.com/documents/investors/esc%5fbms%5f08282011%5fwebcast%5ffinal1. pdf
2. Bristol Myers Squibb. ELIQUIS (apixaban) Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement. Available from URL: www.bms.com, 21 May 2011 Media Release
3. Bristol-Myers Squibb Company. Bristol-Myers Squibb Reports Strong Sales, Earnings Performance in First Quarter. Available from URL: www.bms.com, 29 Apr 2010 Media Release
4. EMA. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 March 2011. Available from URL: www.ema.europe.eu, 18 Mar 2011 Media Release
5. Bristol-Myers Squibb Company. ADDING MULTIMEDIA Bristol-Myers Squibb And Pfizer Announce Plans To Submit Regulatory Filing For Apixaban In Europe. Available from URL: www.bms.com, 05 Dec 2009 Media Release
6. Bristol-Myers Squibb Company, Pfizer Inc. ELIQUIS (apixaban) Meets Primary and Key Secondary Endpoints in Phase 3 ARISTOTLE Study. Available from URL: www.bms.com, 23 Jun 2011 Media Release
7. Apixaban for Prevention of Acute Ischemic Events-2: A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects With a Recent Acute Coronary Syndrome. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00831441
8. Bristol-Myers Squibb Company, Pfizer. APPRAISE-2 Study with Investigational Compound Apixaban in Acute Coronary Syndrome Discontinued. Available from URL: www.bms.com, 19 Nov 2010 Media Release
9. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome.NEngl J Med 2011 Aug 25; 365: 699-708. Epub 2011 Jul 24
10. A Phase 2, Placebo-Controlled, Randomized, Double-Blinded, Multicenter, Study To Evaluate The Bleeding Profile Of 2.5 mg And 5.0 mg bid. Apixaban In Combination With Standard Therapy In Patients With Recent (less than or equal to 7 Days) Acute Coronary Syndrome (ACS). Available from URL: http://www. clinicaltrials.gov/show/NCT00852397
11. Bristol-Myers Squibb Company, Pfizer Inc. Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds. www.bms.com, 26 Apr 2007 Media Release
12. Frost C, Yu Z, Nepal S, et al. Apixaban, an oral direct, factor XA inhibitor: single-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. 21st Congress of the International Society on Thrombosis and Haemostasis. : abstr. P-M-665, 6 Jul 2007. Available from URL: http://www.isth2007.com
13. Frost C, Yu Z, Moore K, et al. Apixaban, an oral direct factor XA inhibitor: multiple-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. 21st Congress of the International Society on Thrombosis and Haemostasis. abstr. P-M-664, 6 Jul 2007. Available from URL: http://www. isth2007.com
14. Barrett YC, Wang J, Yu Z, et al. Apixaban treatment decreases coagulation activity in patients with acute deepvein thrombosis. 50th Annual Meeting and Exposition of the American Society of Hematology. abstr. 1982, 7 Dec 2008. Available from URL: http://www.hematology.org
15. Barrett YC, Wang J, Knabb R, et al. Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thromb Haemost. 2011 Jan;105(1):181-9. Epub 2010 Oct 12
16. Becker RC, Alexander JH, Newby LK, et al. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost. 2010 Nov; 104 (5): 976-83. Epub 2010 Aug 30
17. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008 May;6(5):820-9. Epub 2008 Feb 25 (Pubitemid 351524543)
18. Pinto DJP, Orwat MJ, Fevig JM, et al. Discovery of BMS-562247, a potent and orally bioavailable coagulation factor Xa inhibitor. 230th National Meeting of the American Chemical Society. (CD-ROM): MEDI abstr. 249 (plus oral), 28 Aug 2005. USA. [English]
19. Wong PC, Watson CA, Crain EJ. Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. J Thromb Haemost. 2008 Oct;6(10):1736-41. Epub 2008 Jul 19
20. Wong P, Watson C, Knabb R, et al. The combination of apixaban, a direct factor Xa inhibitor, with heparin or enoxaparin in rabbits elicits additive antithrombotic effects, with low bleeding. ESC Congress 2008: Annual Congress of the European Society of Cardiology. abstr. 933, 30 Aug 2008. Available from URL: http://www.escardio.org
21. Wong PC, Watson CA, Crain EJ, et al. Potent antithrombotic activity of apixaban, a direct factor XA inhibitor, with minimum bleeding time effect in rabbit models of arterial thrombosis and hemostasis. 21st Congress of the International Society on Thrombosis and Haemostasis. abstr. P-W-656, 6 Jul 2007. Available from URL: http://www.isth2007.com
22. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009 Jan; 37 (1): 74-81. Epub 2008 Oct 2
23. Leil TA, Feng Y, Zhang L, et al. Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Ther 2010 Sep; 88 (3): 375-82. Epub 2010 Aug 4
24. Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010 Mar; 38 (3): 448-58. Epub 2009 Nov 25
25. American Society of Hematology. Studies Examine Risk Factor Prediction and Treatment Regimens for Venous Thromboembolism. Available from URL: www.hematology. org, 04 Dec 2010 Media Release
26. Raskob GE, Gallus AS, Pineo GF, et al. Apixaban versus Enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8564 patients from the ADVANCE 2 and 3 trials. Abstract 192. 52nd Annual Meeting of the American Society of Hematology; 2010 Dec 4-7; Orlando (FL). Available from URL: http://ash.confex.com/ash/2010/ webprogram/Paper28037.html
27. Lassen MR, Gallus A, Raskob GE, et al. ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010 Dec 23; 363 (26): 2487-98
28. Lassen MR, Raskob GE, Gallus A, et al. ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010Mar 6; 375 (9717): 807-15
29. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009 Aug 6; 361 (6): 594-604.
30. Erratum in: N Engl J Med. 2009 Oct 29; 361 (18): 1814
31. Feng Y, Li LY, Shenker M, et al. Exposure-clinical outcome modeling and simulation to facilitate dose selection of apixaban in subjects undergoing elective total knee replacement surgery. 21st Congress of the International Society on Thrombosis and Haemostasis. abstr. P-M-663, 6 Jul 2007. Available from URL: http://www.isth2007.com
32. Levine MN, Deitchman D, Julian J, et al. A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer. 45th Annual Meeting of the American Society of Clinical Oncology. : abstr. e20514, 29 May 2009. Available from URL: http://www.abstract.asco.org
33. Bristol Myers Squibb Company, Pfizer Inc. ELIQUIS (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism with Significantly LessMajor Bleeding in Patients with Atrial Fibrillation in Phase 3 ARISTOTLE Trial. www.bms.com, 28 Aug 2011 Media Release
34. Granger CB, Alexander JH,McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011 Sept 15; 365 (11): 981-92. Epub 2001 Aug 27
35. Connolly SJ, Eikelboom J, Joyner C, et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011 Mar 3; 364 (9): 806-17. Epub 2011 Feb 10
36. Botticelli Investigators, Writing Committe, Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008 Aug;6(8):1313-8. Epub 2008 Jun 6 (Pubitemid 352016310)
37. Bristol-Myers Squibb Company. New AVERROES Data Demonstrate Investigational Apixaban Superior toAspirin in Reducing Stroke and Systemic Embolism in Patients with Atrial Fibrillation Unsuitable for Warfarin Therapy. www.bms.com, 11 Feb 2011. Media Release
38. Ogawa S, ShinoharaY, KanmuriK. Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation-the ARISTOTLE-J study. Circ J 2011 Jul 25; 75(8):1852-9. Epub 2011 Jun 14
39. Bristol-Myers Squibb, Pfizer. Bristol-Myers Squibb and Pfizer Initiate New Study in the Apixaban Phase 3 Clinical Trial Program. Available from URL: www.pfizer.com, 11 Jun 2008 Media Release
40. Bristol-Myers Squibb Company, Pfizer Inc. New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome Patients. Available from URL: www.bms.com, 02 Sep 2008 Media Release
41. APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009 Jun 9; 119 (22): 2877-85. Epub 2009 May 26
42. Wastall P, Nepal S, Frost C, et al. A randomized, blinded, placebo and positive-controlled, crossover study to determine the effect of repeated doses of the factor Xa inhibitor apixaban on the QTc interval. Clinical Pharmacology and Therapeutics. 83 (Suppl. 1): 48, Mar 2008. USA. [English]
43. Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness. Available from URL: http://www.clinicaltrials.gov/ct2/ show/NCT00457002
44. Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism. Available from URL: http://clinicaltrials. gov/ct2/show/NCT00633893